Atlas Trials

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

Clinical trial NCT05498896 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05498896
Sponsor
Queen Mary University of London
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2018-12-19
Primary completion
2026-08-31
Enrollment
146

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.